Looking for Sentiment Analysis? Discover the most popular stocks on Reddit by using our Sentiment Tracker
Market Cap 235.92M P/E - EPS this Y 82.40% Ern Qtrly Grth -
Income -20.23M Forward P/E -1.90 EPS next Y -339.30% 50D Avg Chg 13.00%
Sales 81.63M PEG -0.87 EPS past 5Y - 200D Avg Chg -34.00%
Dividend N/A Price/Book 0.80 EPS next 5Y 16.40% 52W High Chg -75.00%
Recommedations 2.70 Quick Ratio 21.84 Shares Outstanding 62.40M 52W Low Chg 70.00%
Insider Own 1.62% ROA -6.89% Shares Float 40.29M Beta 2.24
Inst Own 99.67% ROE -7.37% Shares Shorted/Prior 11.40M/8.15M Price 3.82
Gross Margin 9.02% Profit Margin -24.79% Avg. Volume 720,272 Target Price 5.29
Oper. Margin 65.62% Earnings Date Nov 5 Volume 367,973 Change 2.96%
About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing products for improving the lives of patients with genetically defined diseases in the areas of high unmet medical need in the United States. Its product candidates are losmapimod, a small molecule for the treatment of facioscapulohumeral muscular dystrophy is under phase III clinical trial; and pociredir, a fetal hemoglobin inducer for the treatment of sickle cell disease and beta-thalassemia is under phase I clinical trial. The company is also discovering drug targets for the treatments of rare neuromuscular, muscular, central nervous system, and hematologic disorders, as well as cardiomyopathies and pulmonary diseases. It has collaboration and license agreement with Acceleron Pharma Inc. to identify biological targets to modulate specific pathways associated with a targeted indication within the pulmonary disease space; MyoKardia, Inc. to discover and develop therapies for the treatment of genetic cardiomyopathies; and Sanofi for the development and commercialization of losmapimod, an oral small molecule being investigated for the treatment of facioscapulohumeral muscular dystrophy. Fulcrum Therapeutics, Inc. was Incorporated in 2015 and is headquartered in Cambridge, Massachusetts.

Fulcrum Therapeutics, Inc. News
10/11/24 Fulcrum Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
10/09/24 Fulcrum Therapeutics Inc (FULC) Q2 2024 Earnings Call Highlights: Strong Financial Performance ...
10/09/24 Fulcrum Stock Tanks 58% in a Month: Buying Opportunity or Risky Bet?
10/07/24 FMR LLC's Strategic Reduction in Fulcrum Therapeutics Inc Shares
10/04/24 Down -57.53% in 4 Weeks, Here's Why Fulcrum Therapeutics (FULC) Looks Ripe for a Turnaround
09/17/24 RA Capital Management's Strategic Acquisition of Fulcrum Therapeutics Shares
09/16/24 Fulcrum Therapeutics (FULC) Loses -65.58% in 4 Weeks, Here's Why a Trend Reversal May be Around the Corner
09/13/24 FULC Stock Falls as Muscle Disorder Study Misses Primary Goal
09/12/24 Fulcrum Therapeutics Suspends Rare Muscular Disease Candidate After Disappointing Data From Pivotal Trial
09/12/24 Fulcrum shares collapse as Sanofi-partnered muscular dystrophy drug fails key test
09/12/24 Fulcrum Therapeutics Announces Topline Results from Phase 3 REACH Clinical Trial of Losmapimod in Facioscapulohumeral Muscular Dystrophy (FSHD)
09/10/24 Xencor Stock Gains 23% on Encouraging Pipeline Advancements
09/10/24 Summit Hits Record High on Lung Cancer Drug Topping Merck's Keytruda
09/09/24 Fulcrum Therapeutics Upgraded: BofA Debates Pivotal Study Success For Losmapimod In Rare Genetic Muscle Disease
09/05/24 BioMarin Posts '27 Biz View, Outlines Growth Plans for Next 10 Years
08/30/24 JNJ Seeks First FDA Nod for Autoimmune Disease Drug Nipocalimab
08/30/24 Merck Scraps Two Late-Stage Keytruda Studies on Disappointing Data
08/29/24 Neurocrine Stock Down 19% on Mixed Schizophrenia Study Results
08/28/24 Pfizer Follows Lilly's Example, Unveils DTC Service for Selling Drugs
08/28/24 One Fulcrum Therapeutics Insider Raised Their Stake In The Previous Year
FULC Chatroom

User Image ChartGeek Posted - 5 hours ago

@StocksAndhookers $FULC if prints above 3.62 today then you can hope for 5.50 range .. if not higher chances to crawl down

User Image StocksAndhookers Posted - 20 hours ago

$FULC ANyone here know anything

User Image StocksAndhookers Posted - 4 days ago

$FULC Starting to believe that this can be in the $1 range until they come up with a SCD update which is not expected until 2025

User Image ChartGeek Posted - 4 days ago

@BallzofSTEAL New update on $FULC , with the breakdown below 3.38 today , expected to go to 1 range and then reverse and may move towards 5.50 range. So I got out of this trade and invested in $NVDA . Basically $FULC was my day trade the day I entered and since I didn't set up the stop loss ended up holding it loosing 1.30 cents per stock. One of my bad trades ..

User Image StocksAndhookers Posted - 4 days ago

$FULC This is making me sick. Everyday it's a 4-6% drop. This is going under 3 it seems. WTF. Someone is dumping bc they know something is not right.

User Image StocksAndhookers Posted - 4 days ago

$FULC Is 3.30's support or can we anticipate significantly more downside until we hear hopefully positive news on pioneer study. Have a lot of money riding on this play. Already down a lot and can't tolerate another leg drop.

User Image StocksAndhookers Posted - 6 days ago

$FULC Anyone is feelen a bit of optimism despite being down 60% from the 9's.

User Image StocksAndhookers Posted - 6 days ago

$FULC FMR LLC sold dumped 1.5 million shares, reducing their holdings by 50%. That's why we are now in mid 3.5's. Hope others don't follow suit.

User Image StocksAndhookers Posted - 1 week ago

$FULC Why did we slide 6% today? This is not looking good.

User Image rclark3311 Posted - 1 week ago

$FULC https://finance.yahoo.com/news/ra-capital-managements-strategic-acquisition-053018976.html/

User Image StocksAndhookers Posted - 1 week ago

$FULC Seem very stable at this range. Don't anticipate a sudden iceburg drop. But u never know. My gut instinct is that this stock will revisit $7 based on very positive news on pioneer study. Patience is the key here.

User Image StocksAndhookers Posted - 1 week ago

$FULC If the SCD study makes it to phase 2 on pipeline then this stock can get back to the 8's+. However, I am not holding my breath. Remember it's the SCD study that caused the clinical hold that crashed this stock. If Pfizer couldn't do it then no one else can. They have the funds to do whatever it takes. Unless this company gets some Pfizer money to help with research that would be amazing. The future of this company is on the SCD study.

User Image PKlee Posted - 1 week ago

$FULC -from Seeking Alpha: Jonathan Block, SA News Editor. Fulcrum Therapeutics swings up 17% on Pfizer sickle cell drug setback Shares of Fulcrum Therapeutics (NASDAQ:FULC) are surging ~17% Thursday as the company's sickle cell therapy asset, pociredir, is seen benefitting from Wednesday's announcement that Pfizer (PFE) was recalling its sickle cell treatment Oxbryta (voxelotor) over safety concerns. While pociredir is in phase 1, like Oxbryta, it is an oral medication and trial enrollment could be bolstered by Pfizer's setback, says Leerink Partners analyst David Risinger. "We believe that the withdrawal of Oxbryta could potentially unleash the handful of patients needed in PIONEER," the current phase 1b study," he added.

User Image ChartGeek Posted - 1 week ago

$FULC 6.60 is my nearest target

User Image Stockboi_ Posted - 1 week ago

$FULC reminds me of $SLQT but it’s toppy. Don’t do large adds at this range, manage risk first

User Image DipBuyInvester Posted - 1 week ago

$FULC TANH Crazy move is on the way!!

User Image StocksAndhookers Posted - 1 week ago

$FULC What's the next news on this?

User Image StocksAndhookers Posted - 09/30/24

$FULC 3.15 by the end of the week

User Image StocksAndhookers Posted - 09/28/24

$FULC This stock is gonna trick down to $2. Mark this post. The reach study is cancelled. No sanofi money. No big partnerships. SCD study caused a clinical hold a year ago sinking this stock. Now they are down sizing staff. Those staff members will eventually liquidate holdings. It's just RED all around. WIsh is wasn't so. We were rug pulled. Maybe even fooled.

User Image StocksAndhookers Posted - 09/27/24

$FULC I predict we trickle down to low 2's. If no promising news it will stay there and than drop more. I think it's gonna be a slow death. They already reducing workforce.

User Image StocksAndhookers Posted - 09/27/24

$FULC Boy is this bad---nearly hit $5 and slid back down to mid 3's. WTF is going on? Any hope with this play? Is it worth betting on? I don't see this SCD test taking off. Remember, it's what caused the clinical hold and caused the first massive drop. Went from 14 to 5ish and then slid all the way down to low 2's. You had to have ballz of steal to of held.

User Image PLATINUM_TRADES Posted - 09/26/24

$FULC $4.75 high we got some good profits here.. Alway appreciate any green

User Image StocksAndhookers Posted - 09/26/24

$FULC Not looking good. It's trickling down and close to going under $4. Seemed like a fake pop to trap people. Or it could be the beginning of a squeeze. Not sure. Anyone any thoughts?

User Image BallzofSTEAL Posted - 09/26/24

$FULC Could we be seeing a short squeeze? or is this rise to trap newcomers? Can't believe we popped to 4.74. I really hope we get back to the 8's and 9's. How likely is that?

User Image LewisDaKat Posted - 09/26/24

$FULC News Fulcrum Therapeutics Inc. (NASDAQ: FULC) Leading the Way in Thursday Trading Based on Percentage Gain https://marketwirenews.com/news-releases/fulcrum-therapeutics-inc-nasdaq-fulc-leading-the-way-5327539322566115.html $FULC

User Image Jaybooggy Posted - 09/26/24

$FULC trying to reverse here

User Image PensionPulse Posted - 09/26/24

$FULC RA Capital and RTW are top holders, scaling in slowly here, like what I see...

User Image topstockalerts Posted - 09/26/24

Top Gainers PT2 $SSBI $GOTU $FULC $JZ $ATMCR Details: https://topstockalerts.com/market-gainers-and-losers/

User Image jParkz Posted - 09/26/24

$FULC News Article Bronstein, Gewirtz & Grossman, LLC Announces an Investigation Against Fulcrum Therapeutics, Inc. (FULC) and Encourages Shareholders to Learn More About the Investigation https://marketwirenews.com/news-releases/bronstein-gewirtz-grossman-llc-announces-an-investig-6084049002499560.html $FULC

User Image Hemel_Howlader Posted - 09/26/24

$FULC

Analyst Ratings
RBC Capital Sector Perform Sep 13, 24
HC Wainwright & Co. Neutral Sep 13, 24
Leerink Partners Market Perform Sep 12, 24
B of A Securities Underperform Sep 12, 24
Stifel Hold Sep 12, 24
Cantor Fitzgerald Neutral Sep 12, 24
B of A Securities Neutral Sep 9, 24
HC Wainwright & Co. Buy Aug 1, 24
Cantor Fitzgerald Overweight Jul 10, 24
Insider Trades Relationship Date Transactions Cost($) #Shares Value($) #Share Own SEC Form 4
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Jan 20 Buy 13.00 1,923,076 24,999,988 11,609,704 01/24/23
Gould Robert J Interim President &.. Interim President & CEO Jan 13 Sell 15.00 6,766 101,490 499,864 01/13/23
RA CAPITAL MANAGEMENT, L.P. 10% Owner 10% Owner Dec 27 Buy 5.9941 4,089 24,510 9,505,925 12/29/22
Gould Robert J Director Director Jun 07 Option 7.84 71,435 560,050 578,065 06/08/22
Gould Robert J Director Director Jun 07 Sell 8.09 71,435 577,909 506,630 06/08/22
Gould Robert J Director Director Jun 02 Option 7.84 66,622 522,316 531,012 06/06/22
Gould Robert J Director Director Jun 02 Sell 7.99 66,622 532,310 506,630 06/06/22
Gould Robert J Director Director Apr 07 Option 7.84 5,631 44,147 512,261 04/11/22
Gould Robert J Director Director Apr 07 Sell 24.02 5,631 135,257 506,630 04/11/22
Gould Robert J Director Director Apr 01 Option 7.84 94,251 738,928 559,182 04/05/22
Gould Robert J Director Director Apr 01 Sell 24.1 94,251 2,271,449 506,630 04/05/22